Contrast-enhanced wideband harmonic imaging ultrasound (SonoVue): a new technique for quantifying bowel wall vascularity in Crohn's disease

Scand J Gastroenterol. 2005 Aug;40(8):985-91. doi: 10.1080/00365520510015818.

Abstract

Objective: To assess the possibility of quantitative determination of bowel wall vascularity using contrast-enhanced (SonoVue) wideband harmonic imaging ultrasound and the HDI-Lab software in patients with Crohn's disease.

Material and methods: Twenty-one patients (13 F, 8 M, average age 33.8+/-12.7 years, range 21-60 years) with histologically confirmed Crohn's disease and bowel wall thickness > or -5 mm were recruited for the study. All ultrasound examinations were performed using a Philips HDI 5000 scanner. Bowel wall vascularity was determined at the site of maximum bowel wall thickness at baseline and at 30, 60, 90 and 120 s following application of the contrast enhancer SonoVue (1.2 ml) using the HDI-Lab software.

Results: The mean length of bowel segments exhibiting increased wall thickness was 122.3 mm (range: 23-350+/-74.7 mm), with a mean wall thickness of 7.6+/-1.2 mm. Onset of echo enhancement secondary to contrast medium application was observed after an average 13.4 s (range 7-19+/-4.2 s). Echo intensity corresponding to maximum vascularity was measured 30 s after application of contrast medium. Maximum average contrast medium uptake was 217.5% (range 118-466+/-100.1%).

Conclusions: It is possible to quantify bowel wall vascularity accurately in patients with Crohn's disease using contrast-enhanced pulse inversion ultrasound (low-MI).

Publication types

  • Comparative Study

MeSH terms

  • Adult
  • Crohn Disease / diagnostic imaging*
  • Feasibility Studies
  • Female
  • Humans
  • Ileitis / diagnostic imaging*
  • Ileum / blood supply*
  • Ileum / diagnostic imaging
  • Injections, Intravenous
  • Male
  • Middle Aged
  • Phospholipids* / administration & dosage
  • Prospective Studies
  • Reproducibility of Results
  • Sulfur Hexafluoride* / administration & dosage
  • Ultrasonography, Doppler / methods*

Substances

  • Phospholipids
  • contrast agent BR1
  • Sulfur Hexafluoride